Prosecution Insights
Last updated: November 19, 2026

Selecta Biosciences Inc.

Technology area: Biotechnology & Pharmaceuticals

3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready

Analysis

Selecta Biosciences Inc. maintains a presence in the Biotechnology & Pharmaceuticals technology area with 3 pending office actions currently active. These actions are distributed across 3 distinct examiners, indicating a diverse range of perspectives within the USPTO. This distribution requires the applicant to manage multiple prosecution tracks simultaneously.

The portfolio is further spread across 3 distinct art units. This variety suggests that the underlying technologies may span different specialized niches within the broader biotechnology field. HUYNH, PHUONG N is identified as the busiest examiner for the company, currently responsible for 1 busiest examiner pending action.

With 3 pending office actions and 3 distinct examiners, each matter is being handled by a different individual. The presence of 3 distinct art units means that the prosecution strategy must be tailored to the specific requirements of different administrative groups. Since the busiest examiner pending count is 1, the workload is distributed among the assigned examiners, with no 1 individual managing all pending matters.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

3
Total Pending OAs
1
Non-Final OAs
2
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

0
Overdue
0
Due this week
1
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
2
Medium (67%)
1
Easy (33%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only1 (33%)
Double-patenting only1 (33%)
Double-patenting + other1 (33%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

3
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

30 h
Manual time on pending OAs
6 h
Time saved (low, 20%)
10 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
HUYNH, PHUONG N 1 65.9% +53.6%
CURRENS, GRANT CARSON 1 54.5% +60.4%
LIU, TRACY 1 54.3% +26.3%

Interview Candidates (3)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
17092148 FORMULATIONS AND DOSES OF PEGYLATED URICASE CURRENS, GRANT CARSON 26d
18177714 TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE IMMUNE RESPONSES TO THERAPEUTIC PROTEINS HUYNH, PHUONG N —
14934132 METHODS AND COMPOSITIONS RELATED TO THE USE OF LOW HLB SURFACTANTS IN THE PRODUCTION OF SYNTHETIC NANOCARRIERS COMPRISING A RAPALOG LIU, TRACY —

Top Art Units

Art UnitApps
1641 1
1651 1
1614 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18177714 TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE IMMUNE RESPONSES TO THERAPEUTIC PROTEINS HUYNH, PHUONG N 1641 DP Final Rejection — Pending Mar 02, 2023
17092148 FORMULATIONS AND DOSES OF PEGYLATED URICASE CURRENS, GRANT CARSON 1651 §103Other Final Rejection 26d Pending Nov 06, 2020
14934132 METHODS AND COMPOSITIONS RELATED TO THE USE OF LOW HLB SURFACTANTS IN THE PRODUCTION OF SYNTHETIC NANOCARRIERS COMPRISING A RAPALOG LIU, TRACY 1614 §103DP Non-Final OA — Pending Nov 05, 2015

Managing Selecta Biosciences Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Selecta Biosciences Inc. have?

Selecta Biosciences Inc. has 3 pending office actions as of November 2026, spread across 3 art units and 3 examiners.

Which USPTO examiner handles the most Selecta Biosciences Inc. applications?

Phuong N Huynh has the most, with 1 of Selecta Biosciences Inc.'s pending office actions.

What technology area are Selecta Biosciences Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month